In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'mTOR inhibitor'
Please login to view adverse reactions.
Acneiform eruption / acneiform dermatitis / acneiform rash
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367>10% [REVIEW]
Cutaneous toxicity / skin toxicity
- (2015): Macdonald JB+, J Am Acad Dermatol 72(2), 221 [REVIEW]
- (2015): Somers MJ+, J Clin Pharmacol 55(4), 368 [REVIEW]
- (2014): Grellety T+, Bull Cancer (French) 101(6), 608
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW] (ovarian)
- (2014): Caletti C+, G Ital Nefrol (Italian) 31(4), Epub
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367>10% [REVIEW]
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367 [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367>10% [REVIEW]
- (2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]
- (2015): Shameem R+, Cancer Invest 33(3), 7034%
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2013): Boers-Doets CB+, Future Oncol 9(12), 1883 [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367>10% [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2016): Lew S+, Anticancer Res 36(4), 1711 [REVIEW]
- (2014): Murakami N+, Am J Transplant 14(10), 2317 [REVIEW]
Hyperglycemia (includes glucose increased)
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367 [REVIEW]
- (2016): Lew S+, Anticancer Res 36(4), 1711 [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
Hypertriglyceridemia (includes triglycerides increased)
- (2016): Lew S+, Anticancer Res 36(4), 1711 [REVIEW]
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367 [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2014): Murakami N+, Am J Transplant 14(10), 2317 [REVIEW]
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367>10% [REVIEW]
- (2014): Caletti C+, G Ital Nefrol (Italian) 31(4), Epub
- (2015): Fusco V+, Clin Genitourin Cancer 13(4), 287 [REVIEW]
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367>10% [REVIEW]
- (2014): Kaplan B+, Transplant Rev (Orlando) 28(3), 126 [REVIEW]
- (2014): Murakami N+, Am J Transplant 14(10), 2317 [REVIEW]
- (2017): Fernandes-Silva G+, Expert Opin Drug Metab Toxicol 13(4), 367 [REVIEW]
- (2016): Willemsen AE+, Int J Cancer 138(10), 2312 [REVIEW]
- (2014): Caletti C+, G Ital Nefrol (Italian) 31(4), Epub
- (2016): Sadowski K+, Pharmacol Rep 68(3), 536 [REVIEW]
